iShares Biotechnology ETF (IBB)
| Assets | $6.47B |
| Expense Ratio | 0.45% |
| PE Ratio | 17.32 |
| Shares Out | 48.95M |
| Dividend (ttm) | $0.39 |
| Dividend Yield | 0.29% |
| Ex-Dividend Date | Dec 17, 2024 |
| Payout Ratio | 5.06% |
| 1-Year Return | -0.14% |
| Volume | 1,845,250 |
| Open | 130.73 |
| Previous Close | 131.21 |
| Day's Range | 130.51 - 134.02 |
| 52-Week Low | 123.60 |
| 52-Week High | 150.57 |
| Beta | 0.72 |
| Holdings | 217 |
| Inception Date | Feb 5, 2001 |
About IBB
Fund Home PageThe iShares Biotechnology ETF (IBB) is an exchange-traded fund that is based on the NYSE Biotechnology index. The fund tracks the performance of a modified market-cap-weighted index of US biotechnology companies listed on US exchanges. IBB was launched on Feb 5, 2001 and is issued by BlackRock.
Top 10 Holdings
47.79% of assets| Name | Symbol | Weight |
|---|---|---|
| Gilead Sciences, Inc. | GILD | 10.05% |
| Vertex Pharmaceuticals Incorporated | VRTX | 8.10% |
| Amgen Inc. | AMGN | 6.82% |
| Regeneron Pharmaceuticals, Inc. | REGN | 5.35% |
| IQVIA Holdings Inc. | IQV | 3.61% |
| argenx SE | ARGX | 3.29% |
| Alnylam Pharmaceuticals, Inc. | ALNY | 3.19% |
| Mettler-Toledo International Inc. | MTD | 2.66% |
| BioNTech SE | BNTX | 2.42% |
| Illumina, Inc. | ILMN | 2.30% |
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Dec 17, 2024 | $0.062 | Dec 20, 2024 |
| Sep 25, 2024 | $0.200 | Sep 30, 2024 |
| Mar 21, 2024 | $0.126 | Mar 27, 2024 |
| Dec 20, 2023 | $0.124 | Dec 27, 2023 |
| Sep 26, 2023 | $0.153 | Oct 2, 2023 |
| Jun 7, 2023 | $0.006 | Jun 13, 2023 |
News
iShares Biotechnology ETF: Playing Defense
The biotech sector is very defensive and non-cyclical due to the necessity of medications and healthcare treatment being largely independent of economic growth and market risk sentiment. Money is retu...
Mizuho's Jared Holz on what Trump's FDA pick means for biotech innovation
Mizuho's Jared Holz joins 'Fast Money' to talk what's next for biopharma space after president-elect Trump names his pick for FDA head.
Health care stocks jump on Trump's nominee for FDA head
CNBC's Angelica Peebles joins 'Fast Money' to talk president-elect Trump's pick for FDA head.
Final Trade: Euro, IBB, SMH, NEM
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.
Final Trade: West Pharma, Cameco, iShares Biotechnology ETF and Applied Digital Corp
The final trades of the day with the Fast Money traders.
IBB: A Near-20x P/E Is Historically Pricey, Technical Trends Neutral
I reiterate a hold rating on IBB due to its stretched valuation at nearly 20x earnings and mixed technical situation. Despite a 7% YTD gain, IBB has underperformed the S&P 500, which is up 21%, and sh...
Biotech Stocks Are Showing Signs of Life. Why the Rally Could Continue.
Thanks to the prospect of lower interest rates, shares of biotech companies have doubled the gains of the broad market over the past few months.
Biotech stocks will get a tailwind from rate cuts, says Stempoint's Michelle Ross
Michelle Ross, Stempoint Capital, joins 'Closing Bell' to discuss Eli Lilly after the stock saw a slight dip after rallying.
Analyst is 'extremely bullish' on biopharma
Pfizer (PFE) and Merck (MRK) reported their second quarter earnings, with both companies beating expectations. Grey Ghost Advisors CEO Meghan Fitzgerald joins Catalysts to give insight into Pfizer and...
iShares Biotechnology ETF: Significant Upside Potential As Sector Gains Momentum
Biotechnology companies experienced an optimistic bullish cycle in 2020-2021, leading to outperformance of the Biotech index. But the cycle of interest rate increases taking place since 2022 has cause...
Biotech Stocks 2024 Second Half Outlook - Buy Biotechs
Biotech indexes lagged broader market indexes in the first half of 2024, and trade at the same level as in early 2022. Biotech valuations are closely tied to the Fed's interest rate policy and are hig...
For Biotech Stocks To Move Higher, This Must Move Lower
Biotech indexes, represented by IBB and XBI, have been facing pressure since March and trading at valuations seen in April 2020. The key factor influencing biotech valuations, discussed below, is expe...
This weight-loss ETF has performed well in its first five months. How does it compare with cheaper alternatives?
A new exchange-traded fund needs an edge to attract investors. This might be its industry focus — a tall order in a crowded market with ETFs covering just about any industry you can imagine.
Biotech's Next Gold Rush: Weight-Loss Drugs
Biotech's next gold rush is weight-loss drugs. There is a dominance of NVO and LLY in this space for now, notes Rahul Jasuja.
Catch The Medical Breakthroughs With The IBB ETF
IBB tracks the performance of the rapidly advancing biotechnological sector. The need for advanced medical innovations is urgent to challenge serious ailments. The fund could benefit investors with up...
IBB: Let It Rest
The iShares Biotechnology ETF has underperformed the broader market and remains in the range set last year. Heavily weighted top 10 stocks have flat revenues are are no longer growth stocks. Further u...
Why Biotech Stocks May Be Ready For A Recovery
Jared Ablass, Vice President, Portfolio Research at TD Asset Management, speaks with Greg Bonnell about how the biotech sector could benefit once rates start to come down. Why beaten down Biotech stoc...
Navigating the big run in biotech
The 'Halftime Report' Investment Committee debates the upside potential in the biotech space.
Health care's underperformance last year sets it up well for 2024, says Mara Goldstein
Mara Goldstein, Biotech Analyst at Mizuho, discusses health care's outperformance this week.
Healthcare In 2024: Navigating The Biopharma Bull Run
The healthcare sector presents a unique investment opportunity in 2024 due to attractive valuation and uncorrelated/robust cashflow of healthcare. Biopharma companies have pricing power and ability to...
Equity CEFs/ETFs: Top Picks For 2024 - Part II
In Part I of my Top Picks For 2024, I explained why we saw such extreme valuation losses in most equity CEFs in 2023 and what that could-mean for 2024. In my opinion, liquidity was the over-riding fac...
Dr. Scott Gottlieb talks Big Pharma's buying spree
Dr. Scott Gottlieb, joins 'Closing Bell' to discuss the government's regulation on the pharmaceutical industry.
Wedbush's Laura Chico talks biotech investing in 2024
Laura Chico, Wedbush Biotech Analyst, joins 'Closing Bell Overtime' to talk investing in biotech.
Buy or bail on biotech: Here's what you need to know
Biotech is up double digits this month. Piper Sandler says that the sector is breaking out.
Biotech Stocks Are Breaking Out—and They Show No Sign of Slowing Down
Shares have gotten a boost from the Fed and from M&A.